Cluster Headache Clinical Trial
Official title:
Safety and Efficacy of Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache: a Randomized, Double-blind, Placebo-controlled Phase II Study
Background: After no official research in humans in the last 40 years, research and therapeutic uses of the serotonergic psychedelic lysergic acid diethylamide (LSD) are now re-recognized and include its use in brain research, alcoholism, anxiety associated with terminal illness, and treatment of headache disorders. Specifically, LSD has been reported to abort attacks, to decrease frequency and intensity of attacks, and to induce remission in patients suffering from cluster headache (CH). Objective: To investigate the effects of an oral LSD pulse regimen (3 x 100 µg LSD in three weeks) in patients suffering from CH compared with placebo. Design: Double-blind, randomized, placebo-controlled two-phase cross-over study design. Participants: 30 patients aged ≥ 25 and ≤ 75 years with chronic or episodic CH with predictable periods lasting approximately 2 months and attacks responding to oxygen. Main outcome measures: Changes in frequency and intensity of CH attacks assessed with a standardized headache diary Significance: CH is often rated as the most painful of all primary headaches, which not only causes significant disability, but is also associated with enormous personal, economic, and psychiatric burden. At the moment, there is no specific treatment available for CH, but serotonergic compounds represent an important drug class, especially in the abortive management of cluster attacks. However, there is a need for new treatment approaches, as CH is also often insufficiently managed with available medication. This study will evaluate the potential benefit and safety of a treatment with LSD for patients with CH.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05264714 -
Cluster Headache Treatment With Rimegepant
|
Phase 2 | |
Completed |
NCT01677026 -
Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
|
||
Terminated |
NCT00203190 -
A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache
|
Phase 4 | |
Terminated |
NCT04570475 -
High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache
|
Phase 3 | |
Completed |
NCT04066023 -
Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04353505 -
Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
|
Phase 1 | |
Completed |
NCT02019017 -
Botox Injection in Treatment of Cluster Headache
|
Phase 1/Phase 2 | |
Completed |
NCT05153876 -
An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
|
||
Recruiting |
NCT05324748 -
Repeated GON Injections in CCH
|
Phase 3 | |
Completed |
NCT02782533 -
DBS of the Third Ventricle for Cluster Headache and Obesity
|
N/A | |
Completed |
NCT04179266 -
Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache
|
Phase 1/Phase 2 | |
Recruiting |
NCT04406259 -
Atrioventricular Block and Cluster Headache (SEVA)
|
Phase 4 | |
Recruiting |
NCT06206772 -
Resting State Functional Connectivity in Cluster Headache
|
||
Recruiting |
NCT03944876 -
Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache
|
Phase 3 | |
Not yet recruiting |
NCT05857098 -
Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
|
||
Recruiting |
NCT02910323 -
The Will Erwin Headache Research Center - Cluster Headache Study
|
||
Terminated |
NCT00458770 -
Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks
|
N/A | |
Completed |
NCT00662935 -
Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH)
|
N/A | |
Active, not recruiting |
NCT03511846 -
Pain Biomarker Study
|
Phase 1 | |
Completed |
NCT00184587 -
Prophylactic Treatment of Episodic Cluster Headache
|
Phase 2 |